Catalyst Pharmaceuticals files new drug application with FDA

Catalyst Pharmaceuticals has submitted a new drug application (NDA) to the U.S. Food and Drug Administration, bringing the Coral Gables-based drug maker one step closer to launching Firdapse, a treatment for a rare degenerative neuromuscular disease. Founded in 2002, Catalyst (Nasdaq: CPRX) has been working to develop Firdapse for almost a decade, a common timeline in the highly regulated pharmaceutical industry. Firdapse aims to treats symptoms of Lambert-Eaton myasthenic syndrome, a degenerative…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news